The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease

European Heart Journal

Volumn 20, Issue 8, 1999, Pages 584-592

  Gardemann, A ^a   Weidemann, H ^a   Philipp, M ^a   Katz, N ^a   Tillmanns, H ^a   Wilhelm Hehrlein, F ^c   Haberbosch, W ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

^c Klin Herz Gefasschirurgie J ^*

Author keywords

Coronary artery disease; Coronary risk factors; Homocysteine metabolism; Myocardial infarction

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; GLUCOSE; LIPOPROTEIN;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DNA POLYMORPHISM; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; CORONARY ARTERIOSCLEROSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0032941872     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1340     Document Type: Article

References (58)

1. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 27:1996;517-527.
2. Welch GN, Loscalzo L. Homocysteine and atherothrombosis. N Engl J Med. 338:1998;1042-1050.
3. Miner SES, Evrovski J, Cole DEC. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem. 30:1997;189-201.
4. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med. 291:1974;537-543.
5. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 58:1976;731-741.
6. James TN. The spectrum of diseases of small arteries and their physiologic consequences. J Am Coll Cardiol. 15:1990;763-774.
7. Stamler JS, Osborne JA, Jaraki O. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
8. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem. 41:1995;361-366.
9. Welch GN, Upchurch GR Jr, Loscalzo J. Hyperhomocysteinaemia and atherothrombosis. Ann N Y Acad Sci. 811:1997;48-58.
10. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 77:1986;1909-1916.
11. Ratnoff OD. Activation of Hageman factor by Lhomocysteine. Science. 162:1968;1007-1009.
12. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 75:1990;895-901.
13. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906-1914.
14. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 92:1993;1381-1386.
15. Tsai J-C, Perrella MA, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U.S.A. 91:1994;6369-6373.
16. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest. 98:1996;5-7.
17. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 34:1993;2051-2061.
18. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochem Biophys Acta. 917:1987;337-340.
19. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Biochem. 93:1993;1764-1779.
20. Kang SS, Zhou J, Wong PWK, Kowalysin J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylentetrahydrofolate reductase. Am J Hum Genet. 43:1988;414-421.
21. Frosst P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nature Genetics. 10:1995;111-113.
22. Ou T, Yamakawa Kobayashi K, Arinami T. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis. 137:1998;23-28.
23. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis. 136:1998;347-354.
24. Kluijtmans LAJ, Lambert PWJ, van den Heuvel LPWJ. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutuation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 58:1996;35-41.
25. Morita H, Taguchi J, Kurihara H. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
26. Brulhart MC, Dussoix P, Ruiz J, Passa P, Froguel P, James RW. The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients. Am J Hum Genet. 60:1997;228-229.
27. Adams M, Smith PD, Martin D, Thompson JR, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM Monthly J Ass Physicians. 89:1996;437-444.
28. Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Art Thromb Vasc Biol. 16:1996;878-882.
29. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction - a case-control study. Circulation. 94:1996;1812-1814.
30. Ma J, Stampfer MJ, Hennekens CH. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US Physicians. Circulation. 94:1996;2410-2416.
31. Anderson JL, King GJ, Thomson MJ. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 30:1997;1206-1211.
32. Verhoef P, Kok FJ, Kluijtmans LAJ. The 677C->T mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 132:1997;105-113.
33. Schwartz SM, Siscovick DS, Malinow MR. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 96:1997;412-417.
34. Christensen B, Frosst P, Lussier Cacan S. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Art Thromb Vasc Biol. 17:1997;569-573.
35. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 128:1997;107-112.
36. Deloughery TG, Evans A, Sadeghi A. Common mutation in methylenetetrahydrofolate reductase: Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 94:1996;3074-3078.
37. Van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
38. Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest. 28:1998;20-23.
39. Abbate R, Sardi I, Pepe G. The high prevalence of thermolabile 5-10 methylenetetrahydro-folate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haem. 79:1998;727-730.
40. Cambien F, Poirier O, Lecerf L. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
41. Ko YL, Ko YS, Wang SM. Angiotensinogen and angiotensin I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Human Genetics. 100:1997;210-214.
42. Katsuuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R. Association of angiotensinogen gene T235 variant with increased risk of coronary artery disease. Lancet. 345:1995;1600-1603.
43. Tiret L, Bonnardeaux A, Poirier O. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 344:1994;910-913.
44. Blatter Garin M-C, James RW, Dussoix P. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest. 99:1997;62-66.
45. Serrato N, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 96:1995;3005-3008.
46. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
47. Watson AD, Berliner JA, Hama SY. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 96:1995;2882-2891.
48. Gardemann A, Fink M, Stricker J. ACE I/D gene polymorphism: Presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. Atherosclerosis. 139:1998;153-159.
49. Gardemann A, Nguyen QD, Humme J. Angiotensin II type 1 receptor A1166C gene polymorphism: Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with the angiotensin-converting enzyme gene polymorphism on the risk of these diseases. Eur Heart J. 19:1998;1657-1665.
50. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 51:1983;606.
51. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1990;1343-1346.
52. Lindpaintner K, Pfeffer MA, Kreutz R. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 332:1995;706-711.
53. Hegele RA, Brunt H, Connelly PW. A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation. 90:1994;2207-2212.
54. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235->Thr allele of the human angiotensinogen gene. Hum Mol Genet. 2:1993;609-610.
55. Hingorani AD, Brown MJ. A simple molecular assay for the C1166 variant of the angiotensin II type 1 receptor gene. Biochem Biophys Res Commun. 213:1995;725-729.
56. Ruiz J, Blanche' H, James RW. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 346:1995;869-872.
57. Fodinger M, Mannhalter C, Wolfl G. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int. 52:1997;517-523.
58. Jacques PF, Bostom AG, Williams RR. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.